Journal
ARCHIVES OF NEUROLOGY
Volume 69, Issue 3, Pages 352-356Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2011.1974
Keywords
-
Categories
Funding
- Novartis
- Teva Neuroscience
- Guthy Jackson Charitable Foundation
- Biogen Idec
- Greater Good Foundation
- DioGenix
- Amplimmune
- Accelerated Cure Project
- Genzyme
- Genentech
- Alexion
- National Institutes of Health
- National Multiple Sclerosis Society
- Nancy Davis Foundation
- EMD Serono
- Vertex
- Abbott
- Bayer
- ApoPharma Inc
Ask authors/readers for more resources
Background: Low 25-hydroxyvitamin D levels have been associated with a higher risk of developing multiple sclerosis and increased relapse rates in patients with multiple sclerosis. As a sterol hormone involved in multiple immunologic pathways, vitamin D may play a role in preventing monophasic immune-mediated central nervous system attacks from developing into recurrent disease. Objective: To investigate the association between low serum vitamin D levels and recurrent spinal cord disease. Design, Setting, and Patients: We performed a retrospective analysis at Johns Hopkins Transverse Myelitis Center, Baltimore, Maryland, evaluating 25-hydroxyvitamin D levels in 77 patients with monophasic and recurrent inflammatory diseases of the spinal cord. Main Outcome Measure: Levels of 25-hydroxyvitamin D. Results: Vitamin D levels are significantly lower in patients who developed recurrent spinal cord disease, adjusting for season, age, sex, and race. Conclusions: This study provides a basis for a prospective trial of measuring 25-hydroxyvitamin D levels in these patient populations and assessing the influence of vitamin D supplementation on the frequency of relapses in those with recurrent inflammatory spinal cord disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available